Last reviewed 2026-05-18 · How we verify

Boric Acid Vaginal Suppository

Hatem AbuHashim · Phase 1 active Small molecule Quality 55/100

Boric Acid Vaginal Suppository is a Antiseptic and antifungal agent Small molecule drug developed by Hatem AbuHashim. It is currently in Phase 1 development.

Creates an acidic vaginal environment that inhibits growth of pathogenic fungi and bacteria while supporting normal vaginal flora.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Boric Acid Vaginal Suppository
Sponsor	Hatem AbuHashim
Drug class	Antiseptic and antifungal agent
Modality	Small molecule
Phase	Phase 1

Mechanism of action

Boric acid acts as a weak acid that lowers vaginal pH, creating conditions unfavorable for pathogenic organisms including Candida species and bacteria associated with bacterial vaginosis. The acidic environment helps restore normal vaginal flora balance.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Boric Acid Vaginal Suppository CI brief — competitive landscape report
Boric Acid Vaginal Suppository updates RSS · CI watch RSS
Hatem AbuHashim portfolio CI

Frequently asked questions about Boric Acid Vaginal Suppository

What is Boric Acid Vaginal Suppository?

Boric Acid Vaginal Suppository is a Antiseptic and antifungal agent drug developed by Hatem AbuHashim.

How does Boric Acid Vaginal Suppository work?

Creates an acidic vaginal environment that inhibits growth of pathogenic fungi and bacteria while supporting normal vaginal flora.

Who makes Boric Acid Vaginal Suppository?

Boric Acid Vaginal Suppository is developed by Hatem AbuHashim (see full Hatem AbuHashim pipeline at /company/hatem-abuhashim).

What drug class is Boric Acid Vaginal Suppository in?

Boric Acid Vaginal Suppository belongs to the Antiseptic and antifungal agent class. See all Antiseptic and antifungal agent drugs at /class/antiseptic-and-antifungal-agent.

What development phase is Boric Acid Vaginal Suppository in?

Boric Acid Vaginal Suppository is in Phase 1.

Drug class: All Antiseptic and antifungal agent drugs
Manufacturer: Hatem AbuHashim — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing